AR061913A1 - Derivados de aminoindazolurea, procesos de obtencion y composiciones farmaceuticas. - Google Patents
Derivados de aminoindazolurea, procesos de obtencion y composiciones farmaceuticas.Info
- Publication number
- AR061913A1 AR061913A1 ARP070103194A ARP070103194A AR061913A1 AR 061913 A1 AR061913 A1 AR 061913A1 AR P070103194 A ARP070103194 A AR P070103194A AR P070103194 A ARP070103194 A AR P070103194A AR 061913 A1 AR061913 A1 AR 061913A1
- Authority
- AR
- Argentina
- Prior art keywords
- het
- so2n
- mono
- hal
- nhcona2
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
- C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/12—Ophthalmic agents for cataracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Ophthalmology & Optometry (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Obesity (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Rheumatology (AREA)
- Urology & Nephrology (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Gastroenterology & Hepatology (AREA)
- Emergency Medicine (AREA)
- Psychiatry (AREA)
- Child & Adolescent Psychology (AREA)
- Vascular Medicine (AREA)
- Communicable Diseases (AREA)
- Dermatology (AREA)
- Pulmonology (AREA)
- Endocrinology (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
Abstract
Son inhibidores de la SGK y pueden utilizarse para el tratamiento enfermedades causadas por SGK y dolencias tales como diabetes, obesidad, síndrome metabolico (dislipidemia), hipertonía sistémica y pulmonar, enfermedades cardiocirculatorias y enfermedades renales, en general en cualquier tipo de fibrosis y procesos inflamatorios. Reivindicacion 1: Compuestos de la formula (1) en donde R1, R2 son cada uno, de modo independiente entre sí, H, A, -[C(R7)2]nAr, -[C(R7)2]nHet, -COHet o - COAr, R3, R4, R5 son cada uno, de modo independiente entre sí, H, A, Hal, OH, OA, -[C(R7)2]nAr, -[C(R7)2]nHet, OAr, OHet, SH, SA, SAr, SHet, NH2, NHA, NAA', NHAr, N(Ar)2, NHHet, N(Het)2, NAAr, NAHet, SOA, SOAr, SOHet, SO2A, SO2Ar, SO2Het, NO2, CN, COOH, COOA, CONH2, CONHA, CONA2, NHCOA, NACOA, NHCONH2, NHCONHA, NHCONA2, NHSO2A, NASO2A, CHO, COA, COAr, COHet, SO3H, SO2NH2, SO2NHAr, SO2N(Ar)2, SO2NHHet o SO2N(Het)2, X es -CR7R8-, -CR7R8CR9R10- o -CR7R8C(OR9) R10-, Y es Ar o Het, R7, R8, R9, R10 son cada uno, de modo independiente entre sí, H o A, R11 es alquilo C1-6, en donde 1-5 átomos de H pueden estar reemplazados por F, A, A' son cada uno, de modo independiente entre sí, alquilo no sustituido o mono-, di- o trisustituido con R3, =S, =NR7 y/u =O (oxígeno del carbonilo) con 1-10 átomos de C, en donde uno, dos o tres grupos CH2 pueden estar reemplazados por O, S, SO, SO2, NH, NR11 y/o por grupos -CH=CH y/o también 1-7 átomos de H pueden estar reemplazados por F y/o Cl, o alquilo cíclico C3-7, Ar es fenilo, naftilo o bifenilo no sustituido o mono-, di, tri- o tetrasustituido con A, Hal, OH, OA, Ar', OAr', Het, OHet, SH, SA, SAr', SHet, NH2, NHA, NAA', NHAr', N(Ar')2, NHHet, N(Het)2, NAAr', NAHet, SOA, SOAr', SOHet, SO2A, SO2Ar', SO2Het, NO2, CN, COOH, COOA, CONH2, CONHA, CONA2, NHCOA, NACOA, NHCONH2, NHCONHA, NHCONA2, NHSO2A, NASO2A, CHO, COA, COAr', COHet, SO3H, SO2NH2, SO2NHAr', SO2N(Ar')2, SO2NHHet y/o SO2N(Het)2, Het es un heterociclo saturado, insaturado o aromático mono- o bicíclico con 1 a 4 átomos de N, O y/o S, que puede estar mono-, di- o trisustituido con A, Hal, OH, CA, Ar, OAr, Het', OHet', SH, SA, SAr', SHet', NH2, NHA, NAA', NHAr', N(Ar')2, NHHet', N(Het')2, NAAr', NAHet', SOA, SOAr', SOHet', SO2A, SO2Ar', SO2Het', NO2, CN, COOH, COOA, CONH2, CONHA, CONA2, NHCOA, NACOA, NHCONH2, NHCONHA, NHCONA2, NHSO2A, NASO2A, CHO, COA, COAr', COHet', SO3H, SO2NH2, SO2NHAr', SO2N(Ar')2, SO2NHHet' o SO2N(Het')2, =S, =NR7 y/u =O (oxígeno del carbonilo), Ar' es fenilo no sustituido o mono-, di, tri- tetrasustituido con A, Hal, OH, O, Ofenilo, SH, SA, NH2, NHA, NAA', NHfenilo, SOA, SOfenilo, SO2A, SO2fenilo, NO2, CN, COOH, COOA, CONH2, CONHA, CONA2, NHCOA, NACOA, NHCONH2, NHCONHA, NHCONA2, NHSO2A, NASO2A, CHO, COA, COfenilo, SO3H, SO2NH2, SO2NHfenilo y/o SO2N(fenilo) 2, Het' es un heterociclo saturado, insaturado o aromático mono- o bicíclico con 1 a 4 átomos de N, O y/o S, que puede estar mono-, di- o trisustituido con A, Hal, OH, OA, NH2, NHA, NAA', SOA, SOAr', SO2A, SO2Ar', NO2, CN, COOH, COOA, CONH2, CONHA, CONA2, NHCOA, NACOA, NHCONH2, NHCONHA, NHCONA2, NHSO2A, NASO2A, CHO, COA, COAr', SO3H, SO2NH2, SO2NHAr', SO2N(Ar')2, =S, =NR7 y/u =O (oxígeno del carbonilo), Hal es F, Cl, Br o I, n es 0, 1 o 2, así como sus derivados, sales, solvatos y estereoisomeros de utilidad farmacéutica, incluyendo sus mezclas en todas las proporciones.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE102006033140A DE102006033140A1 (de) | 2006-07-18 | 2006-07-18 | Aminoindazolharnstoffderivate |
Publications (1)
Publication Number | Publication Date |
---|---|
AR061913A1 true AR061913A1 (es) | 2008-10-01 |
Family
ID=38779530
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP070103194A AR061913A1 (es) | 2006-07-18 | 2007-07-18 | Derivados de aminoindazolurea, procesos de obtencion y composiciones farmaceuticas. |
Country Status (15)
Country | Link |
---|---|
US (1) | US8207210B2 (es) |
EP (1) | EP2040701B1 (es) |
JP (1) | JP5266218B2 (es) |
KR (1) | KR20090029852A (es) |
CN (1) | CN101489551A (es) |
AR (1) | AR061913A1 (es) |
AU (1) | AU2007276501B2 (es) |
BR (1) | BRPI0714218A2 (es) |
CA (1) | CA2658976C (es) |
DE (1) | DE102006033140A1 (es) |
ES (1) | ES2537195T3 (es) |
IL (1) | IL196364A (es) |
MX (1) | MX2008015440A (es) |
WO (1) | WO2008009335A2 (es) |
ZA (1) | ZA200901127B (es) |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2025674A1 (de) | 2007-08-15 | 2009-02-18 | sanofi-aventis | Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
WO2011107494A1 (de) | 2010-03-03 | 2011-09-09 | Sanofi | Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung |
US8933024B2 (en) | 2010-06-18 | 2015-01-13 | Sanofi | Azolopyridin-3-one derivatives as inhibitors of lipases and phospholipases |
US8530413B2 (en) | 2010-06-21 | 2013-09-10 | Sanofi | Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments |
TW201215387A (en) | 2010-07-05 | 2012-04-16 | Sanofi Aventis | Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament |
TW201215388A (en) | 2010-07-05 | 2012-04-16 | Sanofi Sa | (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments |
TW201221505A (en) | 2010-07-05 | 2012-06-01 | Sanofi Sa | Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament |
WO2013037390A1 (en) | 2011-09-12 | 2013-03-21 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
EP2567959B1 (en) | 2011-09-12 | 2014-04-16 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
EP2760862B1 (en) | 2011-09-27 | 2015-10-21 | Sanofi | 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
MX2015004041A (es) * | 2012-09-28 | 2015-07-06 | Merck Sharp & Dohme | Compuestos novedosos que son inhibidores de erk. |
EP3049085B9 (en) | 2013-09-26 | 2021-08-18 | Beth Israel Deaconess Medical Center, Inc. | Sgk1 inhibitors in the treatment of long qt syndrome |
CA3079786A1 (en) | 2017-10-24 | 2019-05-02 | The Broad Institute, Inc. | 4h-pyrrolo[3,2-c]pyridin-4-one derivatives |
WO2020216773A1 (en) | 2019-04-24 | 2020-10-29 | Bayer Aktiengesellschaft | 4h-pyrrolo[3,2-c]pyridin-4-one compounds |
WO2020216781A1 (en) | 2019-04-24 | 2020-10-29 | Bayer Aktiengesellschaft | 4h-pyrrolo[3,2-c]pyridin-4-one compounds |
EP3958865A1 (en) | 2019-04-24 | 2022-03-02 | Bayer Aktiengesellschaft | 4h-pyrrolo[3,2-c]pyridin-4-one derivatives |
WO2021198020A1 (en) | 2020-03-31 | 2021-10-07 | Bayer Aktiengesellschaft | 3-(anilino)-2-[3-(3-alkoxy-pyridin-4-yl]-1,5,6,7-tetrahydro-4h-pyrrolo[3,2-c]pyridin-4-one derivatives as egfr inhibitors for the treatment of cancer |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6706711B2 (en) * | 2001-04-27 | 2004-03-16 | Vertex Pharmaceuticals Incorporated | Pyrazole derived kinase inhibitor |
WO2003051847A1 (en) | 2001-12-19 | 2003-06-26 | Smithkline Beecham P.L.C. | (1-h-indazol-3-yl) -amide derivatives as gsk-3 inhibitors |
TW200306819A (en) * | 2002-01-25 | 2003-12-01 | Vertex Pharma | Indazole compounds useful as protein kinase inhibitors |
BR0314098A (pt) * | 2002-09-05 | 2005-07-19 | Aventis Pharma Sa | Derivados da aminoindazóis a tìtulo de medicamentos e composições farmacêuticas que os contêm |
US20040209930A1 (en) * | 2002-10-02 | 2004-10-21 | Carboni Joan M. | Synergistic methods and compositions for treating cancer |
WO2004062662A1 (fr) * | 2002-12-12 | 2004-07-29 | Aventis Pharma S.A. | Derives d'aminoindazoles et leur utilisation comme inhibiteurs de kinases |
DE102004028862A1 (de) | 2004-06-15 | 2005-12-29 | Merck Patent Gmbh | 3-Aminoindazole |
TW200738709A (en) * | 2006-01-19 | 2007-10-16 | Osi Pharm Inc | Fused heterobicyclic kinase inhibitors |
-
2006
- 2006-07-18 DE DE102006033140A patent/DE102006033140A1/de not_active Withdrawn
-
2007
- 2007-06-18 KR KR1020097003245A patent/KR20090029852A/ko not_active Application Discontinuation
- 2007-06-18 MX MX2008015440A patent/MX2008015440A/es not_active Application Discontinuation
- 2007-06-18 ES ES07726050.3T patent/ES2537195T3/es active Active
- 2007-06-18 EP EP07726050.3A patent/EP2040701B1/de not_active Not-in-force
- 2007-06-18 AU AU2007276501A patent/AU2007276501B2/en not_active Ceased
- 2007-06-18 JP JP2009519815A patent/JP5266218B2/ja not_active Expired - Fee Related
- 2007-06-18 CA CA2658976A patent/CA2658976C/en not_active Expired - Fee Related
- 2007-06-18 WO PCT/EP2007/005339 patent/WO2008009335A2/de active Application Filing
- 2007-06-18 US US12/374,100 patent/US8207210B2/en not_active Expired - Fee Related
- 2007-06-18 BR BRPI0714218-8A patent/BRPI0714218A2/pt not_active Application Discontinuation
- 2007-06-18 CN CNA2007800269707A patent/CN101489551A/zh active Pending
- 2007-07-18 AR ARP070103194A patent/AR061913A1/es unknown
-
2009
- 2009-01-05 IL IL196364A patent/IL196364A/en not_active IP Right Cessation
- 2009-02-17 ZA ZA200901127A patent/ZA200901127B/xx unknown
Also Published As
Publication number | Publication date |
---|---|
KR20090029852A (ko) | 2009-03-23 |
IL196364A0 (en) | 2009-09-22 |
CA2658976A1 (en) | 2008-01-24 |
WO2008009335A2 (de) | 2008-01-24 |
JP2009543817A (ja) | 2009-12-10 |
WO2008009335A3 (de) | 2008-02-28 |
AU2007276501A1 (en) | 2008-01-24 |
US20090253767A1 (en) | 2009-10-08 |
MX2008015440A (es) | 2008-12-12 |
JP5266218B2 (ja) | 2013-08-21 |
CN101489551A (zh) | 2009-07-22 |
DE102006033140A1 (de) | 2008-01-24 |
ES2537195T3 (es) | 2015-06-03 |
AU2007276501B2 (en) | 2012-01-19 |
CA2658976C (en) | 2014-08-05 |
US8207210B2 (en) | 2012-06-26 |
IL196364A (en) | 2012-12-31 |
EP2040701B1 (de) | 2015-03-18 |
BRPI0714218A2 (pt) | 2013-01-29 |
EP2040701A2 (de) | 2009-04-01 |
ZA200901127B (en) | 2010-01-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR061913A1 (es) | Derivados de aminoindazolurea, procesos de obtencion y composiciones farmaceuticas. | |
AR064952A1 (es) | Derivados de 5-([1, 3, 4]oxadiazol-2-il)-1h-indazol y 5-([1, 3, 4]tiadiazol-2-il)-1h-indazol, un metodo para su preperacion, un kit de elementos que los comprende y su uso en la preparacion de medicamentos para el tratamiento de enfermedades mediadas por la inhibicion de la sgk. | |
AR066557A1 (es) | Derivados de 1h-indazol-5-il-[1, 3, 4]oxadiazol-2-ilo, un metodo para su preparacion, y el uso de los mismos en medicamentos para el tratamiento de enfermedades mediadas por la modulacion de la sgk. | |
AR059908A1 (es) | Derivados de 4-(pirrolopiridinil)-pirimidinil-2-amina | |
AR056958A1 (es) | Acilhidrazidas | |
AR056636A1 (es) | Derivados del acido escuarico | |
AR078313A1 (es) | Derivados de piridinil-imidazolona inhibidores de quinasas pi3k,composiciones farmaceuticas que los comprenden, metodo para prepararlos y uso de los mismos en el tratamiento de enfermedades autoinmunes e inflamatorias, entre otras | |
AR056024A1 (es) | Derivados de acido 3- oxo-indazol-escuarico | |
AR067082A1 (es) | Derivados de indazolamida, proceso de preparacion, medicamentos que los contienen y usos de los mismos, fundamentalmente, como agentes antitumorales y/o antivirales. | |
AR068659A1 (es) | Derivados de imidazol inhibidores de autotaxina | |
AR058205A1 (es) | 5-fenil-3,6-dihidro-2-oxo-6h-[1,3,4] tiadiazinas sustituidas | |
AR070212A1 (es) | Derivados de 4-(pirrolo[2,3-c]piridin-3-il)-pirimidinil-2-amina, proceso de preparacion, medicamentos que los contienen y usos de los mismos para el tratamiento de tumores, metastasis tumoral y/o sida. | |
AR067081A1 (es) | Derivados de pirrolo[2,3-b]piridin-pirimidina,proceso de preparacion, medicamentos que los contienen y usos de los mismos para el tratamiento de tumores cancerigenos y metastasis tumorales. | |
AR071208A1 (es) | Derivados de piridazinona | |
AR067506A1 (es) | Derivados de quinazolinamida | |
AR077567A1 (es) | Derivados de aminopiridina | |
AR049502A1 (es) | Derivados de carbonilo heterociclicos | |
AR072860A1 (es) | Derivados de 3-(3-pirimidin-2-il-bencil)-[1,2,4]triazolo[4,3-b]piridazina | |
AR072148A1 (es) | Derivados de quinoxalindiona | |
AR066892A1 (es) | Derivados de benzoxazolona, proceso, medicamento, uso para tratar tumores y kit | |
AR055772A1 (es) | Aza -heterociclos como inhibidores de quinasas, preparacion de los compuestos y medicamento preparado en base al compuesto | |
AR071530A1 (es) | Derivados de tienopiridonas como activadores de proteina quinasa activa-dos por amp (ampk) | |
AR072192A1 (es) | Derivados de tiazolil-piperidina | |
SV2011003825A (es) | Nuevos derivados de acilaminobenzamida | |
AR074418A1 (es) | Compuestos de benzonaftiridina, procedimiento de preparacion y su uso en el tratamiento de tumores |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |